Marketing-authorisation holder · United States
Boehringer Ingelheim
58 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
58 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 58
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AGGRENOX25MG; 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule, extended release | Acetylsalicylic acid, Dipyridamole | United States | Not marketed | 1999 |
| ALUPENT0.65mg/inh · Aerosol, metered | Metaproterenol | United States | Not marketed | 1973 |
| ALUPENT0.4% | 0.6% | 5% · Solution | Metaproterenol | United States | Not marketed | 1980 |
| ALUPENT10mg/5ml · Syrup | Metaproterenol | United States | Not marketed | 1975 |
| ALUPENT10mg | 20mg · Tablet | Metaproterenol | United States | Not marketed | 1974 |
| APTIVUS250mg · Capsule | Tipranavir | United States | Marketed | 2005 |
| APTIVUS100mg/ml · Solution | Tipranavir | United States | Marketed | 2008 |
| ATROVENT0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Spray, metered | Ipratropium bromide | United States | Not marketed | 1995 |
| ATROVENT0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Ipratropium bromide | United States | Not marketed | 1993 |
| ATROVENT0.018mg/inh · Aerosol, metered | Ipratropium bromide | United States | Not marketed | 1986 |
| ATROVENT HFA0.021mg/inh · Aerosol, metered | Ipratropium bromide | United States | Marketed | 2004 |
| CATAPRES0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Clonidine | United States | Not marketed | 1974 |
| COMBIPRES15MG; 0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 15MG; 0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 15MG; 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Chlorthalidone, Clonidine | United States | Not marketed | 1974 |
| COMBIVENT0.09mg base/inh; 0.018mg/inh · Aerosol, metered | Salbutamol, Ipratropium bromide | United States | Not marketed | 1996 |
| COMBIVENT RESPIMAT0.1mg base/inh; 0.02mg/inh · Spray, metered | Salbutamol, Ipratropium bromide | United States | Marketed | 2011 |
| Cyltezo10mg/0.2ml · Injection | Adalimumab | United States | Marketed | 2022 |
| Cyltezo40mg/0.8ml · Injection | Adalimumab | United States | Marketed | 2023 |
| Cyltezo20mg/0.4ml · Injection | Adalimumab | United States | Marketed | 2018 |
| Cyltezo40mg/0.4ml · Injection | Adalimumab | United States | Marketed | 2024 |
| CYLTEZO40mg/0.8ml · Injectable | Adalimumab | United States | Marketed | 2017 |
| Cyltezo40mg/0.4ml · Injection | Adalimumab | United States | Marketed | 2024 |
| GILOTRIF20mg base | 30mg base | 40mg base · Tablet | Afatinib | United States | Marketed | 2013 |
| GLYXAMBI10mg; 5mg | 25mg; 5mg · Tablet | Empagliflozin, Linagliptin | United States | Marketed | 2015 |
| HERNEXEOS60mg · Tablet | Zongertinib | United States | Marketed | 2025 |
| IV PERSANTINE5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Dipyridamole | United States | Not marketed | 1990 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 58 | 57 | 1 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.